SAUNDERS BRENT L 4
4 · ARS Pharmaceuticals, Inc. · Filed May 22, 2025
Insider Transaction Report
Form 4
SAUNDERS BRENT L
Director
Transactions
- Sale
Common Stock
2025-05-20$14.25/sh−120,000$1,710,024→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-05-20−120,000→ 470,950 totalExercise: $1.01Exp: 2031-06-15→ Common Stock (120,000 underlying) - Exercise/Conversion
Common Stock
2025-05-20$1.01/sh+120,000$121,200→ 120,000 total
Footnotes (2)
- [F1]The weighted average sale price for the transaction reported was $14.2502 and the range of prices were between $14.25 and $14.26. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F2]Immediately exercisable.